Skip to content
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Home (current)
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Adaptimmune

Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs 3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS 1:09
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS
Jo Brewer • 7 Apr 2021
SURPASS: evaluating the next-generation of SPEAR T-cell therapy 1:22
SURPASS: evaluating the next-generation of SPEAR T-cell therapy
Jo Brewer • 7 Apr 2021
Off-the-shelf iPSC therapies for solid tumors 4:23
Off-the-shelf iPSC therapies for solid tumors
Jo Brewer • 7 Apr 2021
The potential of iPSCs in cell therapy 1:28
The potential of iPSCs in cell therapy
Jo Brewer • 7 Apr 2021
Adaptimmune: SPEAR T-cells 6:02
Adaptimmune: SPEAR T-cells
Helen Tayton-Martin • 15 Oct 2020
T-cells: challenges in bringing to market 4:21
T-cells: challenges in bringing to market
Helen Tayton-Martin • 15 Oct 2020
The cell therapy landscape: disruptive technologies 3:12
The cell therapy landscape: disruptive technologies
Helen Tayton-Martin • 15 Oct 2020
The potential of RegenMed in the oncology space 1:41
The potential of RegenMed in the oncology space
Helen Tayton-Martin • 15 Oct 2020
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy